Literature DB >> 23337901

Benefit of conjugate pneumococcal vaccination in preventing influenza hospitalization in children: a case-control study.

Angela Domínguez1, Jesús Castilla, Pere Godoy, Miguel Delgado-Rodríguez, Marc Saez, Núria Soldevila, Jenaro Astray, José María Mayoral, Vicente Martín, José María Quintana, Fernando González-Candelas, Juan Carlos Galán, Sonia Tamames, Ady Castro Acosta, Maretva Baricot, Olatz Garín, Juan José García, Fernando Moraga, Tomás Pumarola.   

Abstract

BACKGROUND: The pneumococcal conjugate vaccine (PCV) might prevent hospitalizations in children because of the role of Streptococcus pneumoniae in the complications of influenza infection. We investigated the benefit of PCV vaccination in preventing influenza hospitalization in children <5 years of age during the 2009 to 2010 pandemic wave and the 2010 to 2011 influenza epidemic in Spain.
METHODS: A multicenter matched case-control study was undertaken in 27 hospitals from 7 Spanish regions between July 2009 and April 2011. A case was defined as a hospitalized patient between 6 months and 5 years of age with influenza virus infection confirmed by real-time reverse-transcription polymerase chain reaction. We selected 2 matched controls for each case from patients with unplanned hospital admission for reasons other than acute respiratory infection or influenza-like illness. Cases and controls were matched according to age, date of hospitalization and province of residence. Crude and adjusted odds ratios were calculated for associations between influenza hospitalization and PCV vaccination.
RESULTS: One hundred ninety-four cases and 342 controls were included in the study. In the 2009 to 2010 pandemic wave, the adjusted benefit in preventing hospitalization was 48% (95% confidence interval: 1 to 76) in fully vaccinated children compared with -79% (95% confidence interval: -341 to 27) in the 2010 to 2011 influenza season.
CONCLUSIONS: The results obtained suggest that, in children <5 years of age, PCV vaccination reduced hospitalization during the 2009 to 2010 pandemic wave. By contrast, there was no observed benefit of vaccination in the 2010 to 2011 influenza season.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337901     DOI: 10.1097/INF.0b013e318280a34b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

Review 1.  Control selection methods in recent case-control studies conducted as part of infectious disease outbreaks.

Authors:  Alison Waldram; Caoimhe McKerr; Maya Gobin; Goutam Adak; James M Stuart; Paul Cleary
Journal:  Eur J Epidemiol       Date:  2015-03-12       Impact factor: 8.082

2.  Burden of Influenza in Less Than 5-Year-Old Children Admitted to Hospital with Pneumonia in Developing and Emerging Countries: A Descriptive, Multicenter Study.

Authors:  Cédric Dananché; Valentina Sánchez Picot; Thomas Bénet; Mélina Messaoudi; Monidarin Chou; Jianwei Wang; Jean-William Pape; Shally Awasthi; Ashish Bavdekar; Mala Rakoto-Andrianarivelo; Mariam Sylla; Pagbajabyn Nymadawa; Graciela Russomando; Florence Komurian-Pradel; Hubert Endtz; Gláucia Paranhos-Baccalà; Philippe Vanhems
Journal:  Am J Trop Med Hyg       Date:  2018-04-12       Impact factor: 2.345

Review 3.  The role of influenza in the severity and transmission of respiratory bacterial disease.

Authors:  Michael J Mina; Keith P Klugman
Journal:  Lancet Respir Med       Date:  2014-08-15       Impact factor: 30.700

Review 4.  Pneumonia in low and middle income countries: progress and challenges.

Authors:  H J Zar; S A Madhi; S J Aston; S B Gordon
Journal:  Thorax       Date:  2013-08-16       Impact factor: 9.139

Review 5.  Viral-bacterial interactions-therapeutic implications.

Authors:  Jane C Deng
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

6.  Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study.

Authors:  Joseph A Lewnard; Katia J Bruxvoort; Vennis X Hong; Lindsay R Grant; Luis Jódar; Alejandro Cané; Bradford D Gessner; Sara Y Tartof
Journal:  J Infect Dis       Date:  2022-03-22       Impact factor: 7.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.